UX701 (5.0 × 10^12 genome copies/kg) ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
171Wilson disease1

171. Wilson disease


Clinical trials : 68 Drugs : 79 - (DrugBank : 17) / Drug target genes : 3 - Drug target pathways : 28
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-005266-34-ES
(EUCTR)
11/02/202206/09/2021A study to understand the safety and the effects of a virus that transfers a modified protein responsible for copper metabolism (copper-transporting P-type adenosine triphosphatase, ATP7B) in adults with Wilson disease.A Randomized, Double-blind, Placebo-controlled, Multicenter, Seamless, Adaptive, Safety, Dose-finding, and Phase 3 Clinical Study of UX701 AAV-mediated Gene Transfer for the Treatment of Wilson Disease - Cyprus2+ Wilson disease
MedDRA version: 20.0;Level: LLT;Classification code 10047988;Term: Wilson's disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: UX701 (5.0 × 10^12 genome copies/kg)
INN or Proposed INN: UX701
Other descriptive name: Adeno-associated viral vector serotype 9 encoding human ATP7B
Product Name: UX701 (1.0 × 10^13 genome copies/kg)
INN or Proposed INN: UX701
Other descriptive name: Adeno-associated viral vector serotype 9 encoding human ATP7B
Product Name: UX701 (2.0 × 10^13 genome copies/kg)
INN or Proposed INN: UX701
Other descriptive name: Adeno-associated viral vector serotype 9 encoding human ATP7B
Ultragenyx Pharmaceutical Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
94Phase 1;Phase 2;Phase 3United States;Portugal;Spain;Austria;Italy;United Kingdom;France;Canada;Argentina;Brazil;Poland;Germany;Japan